JAMA neurology最新文献

{"title":"Aberrant Left-to-Right Fusion of the Oculomotor Nerve.","authors":"Dan Wang, Qing-Lin Chang, Yong-Hong Jiao","doi":"10.1001/jamaneurol.2026.1473","DOIUrl":"10.1001/jamaneurol.2026.1473","url":null,"abstract":"","PeriodicalId":14677,"journal":{"name":"JAMA neurology","volume":" ","pages":"931-932"},"PeriodicalIF":23.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148030504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Amyloid-Targeting Treatments in Patients With Non–Alzheimer Disease Copathologies","authors":"Andy J. Liu, Suzanne E. Schindler, Heather Whitson","doi":"10.1001/jamaneurol.2026.2933","DOIUrl":"https://doi.org/10.1001/jamaneurol.2026.2933","url":null,"abstract":"This Viewpoint examines how clinicians should approach amyloid-targeting therapies in patients with Alzheimer disease and suspected copathologies, emphasizing individualized decision-making, current evidence gaps, and the need for prospective studies.","PeriodicalId":14677,"journal":{"name":"JAMA neurology","volume":"40 1","pages":""},"PeriodicalIF":29.0,"publicationDate":"2026-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148858716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lifelong De Novo Aneurysm Risk After Aneurysmal Subarachnoid Hemorrhage in Young Survivors","authors":"Peter Alpkvist, Caroline Lindblad, Mikael Svensson","doi":"10.1001/jamaneurol.2026.2830","DOIUrl":"https://doi.org/10.1001/jamaneurol.2026.2830","url":null,"abstract":"Importance Young survivors of aneurysmal subarachnoid hemorrhage (aSAH) risk de novo aneurysm formation, yet population-based lifetime estimates are lacking, and prior studies were limited by selection bias and short follow-up. Objective To determine lifetime cumulative incidence, risk factors, and rupture rate of radiologically detected de novo aneurysm formation in young survivors of aSAH and the association with smoking cessation. Design, Setting, and Participants This cohort study used a prospective regional register cross-linked with national health and death registers, with index events from 1967 to 2014. Participants were residents of the Stockholm region, Sweden, and younger than 40 years with an index saccular aSAH. Eligibility required concurrent 4-vessel angiography and retention of original imaging and medical records. Radiological follow-up reached 57 years; de novo aneurysm detection, treatment, recurrent hemorrhage, and vital status were ascertained nationwide through December 31, 2025, and validated longitudinally. Exposures Age, sex, smoking status, family history, hypertension, and multiple aneurysms. Main Outcomes and Measures Cumulative incidence of de novo formation, independent risk factors, annual rupture rate, and smoking-cessation association. Results Of 6521 patients of all ages with regional saccular aSAH, 986 (15.1%) were younger than 40 years. After eligibility criteria were assessed, there were 544 survivors (83.3%). Among them, 313 were female (57.5%) and 231 (42.5%) male; the median (IQR) age was 33 (28-36) years. Over 13 738 person-years, 106 patients (19.5%) developed 158 de novo aneurysms; 23 ruptured. The Fine-Gray cumulative incidence was 30.2% (95% CI, 24.7%-35.7%) at 40 years, without a plateau. Independent risk factors were female sex (hazard ratio [HR], 1.76; 95% CI, 1.16-2.69), smoking (HR, 1.75; 95% CI, 1.13-2.71), and family history (HR, 2.17; 95% CI, 1.22-3.87). Smoking cessation was associated with lower, dose-dependent de novo risk. The annual rupture rate was 153 per 100 000 person-years. No ruptures occurred under systematic surveillance; one-third occurred more than 20 years after the index event. Conclusions and Relevance This study found that young survivors of aSAH face a substantial lifetime risk of de novo aneurysm formation that does not plateau over 4 decades. Female sex, smoking status, and family history are independent risk factors; smoking cessation is a modifiable prevention target. These findings support lifelong surveillance and address current guideline gaps.","PeriodicalId":14677,"journal":{"name":"JAMA neurology","volume":"53 1","pages":""},"PeriodicalIF":29.0,"publicationDate":"2026-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148806388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"TDP-43–Associated Neurodegenerative Disease Conceptualization and Integrated Staging","authors":"Michael Benatar, Sami Barmada, Gregory A. Jicha, Clotilde Lagier-Tourenne, Jenna Gregory, Ammar Al-Chalabi, Bradley F. Boeve, Clifford R. Jack, William W. Seeley, Nicholas J. Maragakis, Joanne Wuu, Zane Zeier, Chiadi Onyike, Joe Lewcock, Collin Hovinga, Paymaan Jafar-nejad, Olga Uspenskaya, Adam Simmons, Susan E. Browne, Jonathan Rohrer, Leonard Petrucelli, Jacquelyn Shapiro, Deb Scharper, Adam Boxer, Lyle W. Ostrow, Adam M. Staffaroni, Penny Dacks, Martin R. Turner, Kuldip D. Dave, Martina de Majo, Laura Mitic, Stephanie Fradette, Samantha Budd Haeberlein, Tanya Simuni, Billy Dunn, Corey T. McMillan, Edward B. Lee","doi":"10.1001/jamaneurol.2026.2812","DOIUrl":"https://doi.org/10.1001/jamaneurol.2026.2812","url":null,"abstract":"Importance Classifying disease based on underlying pathobiology rather than clinical phenotype has implications for the development of biomarkers and therapy development. Observations Transactive response DNA-binding protein 43 kDa (TDP-43) pathology is observed across a range of clinically defined neurodegenerative disorders including limbic predominant age-related encephalopathy (LATE), most cases of amyotrophic lateral sclerosis (ALS), inclusion body myositis, multisystem proteinopathy, and approximately half the cases of frontotemporal dementia (FTD). Despite this shared biology, the current nosology for these neurodegenerative disorders is based on their distinct clinical phenotypes. An alternative approach recognizes the central role of TDP-43 pathology in disease pathogenesis, reserving the use of clinical terms like ALS, FTD, or LATE to describe phenotypic manifestations of underlying pathobiology. This approach also recognizes the converging biomarker and neuropathological data indicating that pathology begins presymptomatically, before the overt clinical manifestations of disease appear. Conclusions and Relevance In proposing a pathobiological definition of disease, the goal is to provide a road map for developing biomarkers that accurately reflect the underlying pathobiology of disease and for advancing therapeutic candidates that effectively target fundamental disease mechanisms.","PeriodicalId":14677,"journal":{"name":"JAMA neurology","volume":"18 6 1","pages":""},"PeriodicalIF":29.0,"publicationDate":"2026-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148806387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety of Antiseizure Medications During Direct Oral Anticoagulant Therapy in Epilepsy","authors":"Kai Michael Schubert, Carolina Ferreira-Atuesta, Arunachalam Soma, Johan Zelano, David J. Seiffge, Francesco Brigo, Eugen Trinka, Nishant K. Mishra, Emilio Russo, Gregory Y. H. Lip, Gashirai K Mbizvo, Marian Galovic","doi":"10.1001/jamaneurol.2026.2712","DOIUrl":"https://doi.org/10.1001/jamaneurol.2026.2712","url":null,"abstract":"Importance Concomitant use of antiseizure medications (ASMs) and direct oral anticoagulants (DOACs) is common in epilepsy, but comparative safety data remain limited. Objective To compare risks of thromboembolic events, major bleeding, and all-cause mortality across commonly used ASMs in adults with epilepsy receiving DOACs. Design, Setting, and Participants This was a retrospective cohort study emulating a target trial for each ASM group against an active comparator; 1:1 propensity score matching in 4 cohorts emulated randomization to estimate the per-protocol outcome of sustained ASM monotherapy. Participant data were acquired from the TriNetX Global Collaborative Network, a federated, deidentified electronic health record platform of 165 health care organizations internationally. Included in the study were adults 18 years or older with epilepsy. Individuals were excluded if there was evidence of recent use of vitamin K antagonists (VKAs) or strong non-ASM cytochrome P450 3A4/P-glycoprotein modulators and if there was a history of major vascular events in the prior year. Participant follow-up began at a prespecified 90-day landmark. Data were analyzed January to March 2026. Exposures ASM monotherapy with levetiracetam, valproate, moderate enzyme-inducing ASMs, or strong enzyme-inducing ASMs (eg, carbamazepine, phenytoin), each vs lamotrigine or lacosamide (1 pooled reference group of patients taking either drug; hereafter referred to as <jats:italic toggle=\"yes\">lamotrigine/lacosamide</jats:italic> ). Main Outcomes and Measures The primary outcomes included primary thromboembolic composite (ischemic stroke, myocardial infarction, pulmonary or systemic/peripheral embolism), major bleeding, and all-cause mortality. Sensitivity analyses included patients treated with VKAs. Results Of 2.29 million adults (≥18 years) with epilepsy, 40 932 were DOAC eligible, 26 962 had DOAC-ASM overlap within 6 months, 10 209 were monotherapy eligible, and 9529 initiators formed the analytic cohort. Among 9529 initiators (mean [SD] age, 63 [18] years; 4869 female [51%]), there were 5473 (57%) taking levetiracetam, 1395 (15%) taking strong enzyme-inducing ASMs, 1006 (11%) taking valproate, and 382 (4%) taking moderate enzyme-inducing ASMs. In matched analyses vs lamotrigine/lacosamide, levetiracetam was associated with higher thromboembolic risk (hazard ratio [HR], 1.98; 95% CI, 1.37-2.87) and higher all-cause mortality (HR, 1.60; 95% CI, 1.23-2.08), with comparable major bleeding. Strong enzyme-inducing ASMs were associated with higher thromboembolic risk (HR, 1.55; 95% CI, 1.02-2.36) but lower major bleeding (HR, 0.62; 95% CI, 0.46-0.83). Valproate was associated with higher mortality (HR, 1.49; 95% CI, 1.09-2.04) and higher intracranial major bleeding (HR, 3.01; 95% CI, 1.45-6.26). Approximately 28% of thromboembolic events were potentially preventable under a lamotrigine/lacosamide reference. In VKA-treated adults, thromboembolic risks were near null. Conclusions","PeriodicalId":14677,"journal":{"name":"JAMA neurology","volume":"140 1","pages":""},"PeriodicalIF":29.0,"publicationDate":"2026-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148754403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-CD320 Autoantibodies and Central Nervous System Vitamin B12 Deficiency in Idiopathic Myelopathy.","authors":"John V Pluvinage, David Acero-Garces, Giacomo Greco, Carson E Moseley, Sukhman Sidhu, Kelsey C Zorn, Sravani Kondapavulur, Sonam Mohan, John Neely, Stefano Masciocchi, Pietro Businaro, Alexis García Sarreón, Ariadna Gifreu Fraixinó, Krista McCutcheon, Colette Caspar, Richard Dela Rosa, Colin Zamecnik, Asritha Tubati, Andoni I Asencor, Madina Tugizova, Felicia Chow, Alexandra Galati, Yair Mina, Camilo Toro, Min Kang, Chu-Yueh Guo, Sarah F Wesley, Kathryn Kvam, Sydney Lee, Ahmed Abdelhak, Thomas Martin, Yun-Han Huang, Sarah B Berman, Jenny Linnoila, John Engstrom, Andrew McCaddon, Ari J Green, Ralph Green, Bruce A C Cree, Stephen L Hauser, Joseph L DeRisi, Samuel J Pleasure, Jeffrey M Gelfand, Gary Álvarez Bravo, Matteo Gastaldi, Carlos A Pardo, Michael R Wilson, Megan Richie, Vanja Douglas, Maulik Shah, Elan L Guterman, Avindra Nath, Catherine G Suen, Martineau Louine, Leah Zuroff, Josiah Gerdts, Mary Karalius, Alyssa Nylander, Carolyn Bevan, Max Liu, Iyas Daghlas, Leena Suleiman, Todd Nguyen, Benjamin Meyer, Karen Ibarra","doi":"10.1001/jamaneurol.2026.2778","DOIUrl":"10.1001/jamaneurol.2026.2778","url":null,"abstract":"<p><strong>Importance: </strong>Disorders affecting the spinal cord (myelopathies) can cause severe disability. Despite diagnostic advances, approximately 12% to 18% of myelopathy cases continue to elude an etiological diagnosis, hampering effective treatment.</p><p><strong>Objective: </strong>To describe a novel autoantibody associated with idiopathic myelopathy (IM) and report its clinical, radiographic, and metabolic characteristics.</p><p><strong>Design, setting, and participants: </strong>This retrospective case-control study was conducted from May 2014 to October 2025 at 4 tertiary care centers. Biofluids from 148 patients diagnosed with IM were evaluated based on clinical evidence of myelopathy without an identified etiology. Biofluids from patients with other neurological diseases (ONDs; n = 32) or known autoimmune myelitis (n = 30) were used for comparison. Proteomewide phage display was used to discover novel autoantibodies. Targeted immunoassays were used to screen for a candidate autoantibody. Downstream metabolites were measured in the cerebrospinal fluid (CSF).</p><p><strong>Exposure: </strong>Autoantibody status.</p><p><strong>Main outcomes and measures: </strong>Prevalence, clinical phenotype, CSF profile, and magnetic resonance imaging pattern of autoantibody-positive IM.</p><p><strong>Results: </strong>Autoantibodies targeting the transcobalamin receptor (CD320) responsible for cellular transport of vitamin B12 were identified in 18 of 32 individuals with IM (56%) in a discovery cohort (mean [SD] age, 54 [14] years; 19 male). Bioactive vitamin B12 concentration was decreased in the CSF of individuals with positive anti-CD320 test results compared with that of control individuals with ONDs (mean [SD], 15.1 [2.3] pmol/L vs 22.9 [10.7] pmol/L; P = .03), indicative of autoimmune vitamin B12 central deficiency. Compared to individuals with IM and negative anti-CD320 test results, those with IM and positive anti-CD320 test results demonstrated a higher frequency of subacute time course (n = 10 [56%] vs n = 1 [7%]; P = .008), normal CSF profile (n = 15 [83%] vs n = 7 [50%]; P = .04), and dorsolateral spinal cord abnormalities on magnetic resonance imaging (n = 11 [61%] vs n = 1 [7%]; P = .003). In 2 independent validation cohorts comprising 91 and 25 patients with IM, anti-CD320 was detected in 41 (45%) and 12 (48%) patients, respectively. Comorbid anti-CD320 antibodies were detected in a smaller proportion of patients with other known autoimmune etiologies of myelopathy. Five individuals with IM and positive anti-CD320 test results received vitamin B12 supplementation with or without concurrent immunosuppression, and 4 of 5 showed clinical improvement.</p><p><strong>Conclusions and relevance: </strong>In this study, autoimmune vitamin B12 central deficiency was associated with IM. Screening for anti-CD320 antibodies followed by metabolic confirmation of a CNS-restricted vitamin B12 deficiency may be considered in the diagnostic evalua","PeriodicalId":14677,"journal":{"name":"JAMA neurology","volume":" ","pages":""},"PeriodicalIF":23.6,"publicationDate":"2026-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13482640/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148793278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Call for Benzodiazepines in Airline Emergency Medical Kits","authors":"Joseph I. Sirven, Caden Collins, Adrian L. Rabinowicz, Enrique Carrazana","doi":"10.1001/jamaneurol.2026.2787","DOIUrl":"https://doi.org/10.1001/jamaneurol.2026.2787","url":null,"abstract":"This Viewpoint discusses the importance of and considerations for including benzodiazepines in airline emergency medical kits for treating patients who experience seizure during a flight.","PeriodicalId":14677,"journal":{"name":"JAMA neurology","volume":"10 1","pages":""},"PeriodicalIF":29.0,"publicationDate":"2026-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148754402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Worsening Spastic Paraparesis After Lumbar Puncture in a Young Adult","authors":"Hui Sun, Lei Wu, Dehui Huang","doi":"10.1001/jamaneurol.2026.2645","DOIUrl":"https://doi.org/10.1001/jamaneurol.2026.2645","url":null,"abstract":"This case report describes a patient with a history of progressive sensory disturbance whose lumbar puncture resulted in acute neurological deterioration due to positional cord compression.","PeriodicalId":14677,"journal":{"name":"JAMA neurology","volume":"23 1","pages":""},"PeriodicalIF":29.0,"publicationDate":"2026-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148698826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plasma Biomarkers for Neocortical Tau Burden","authors":"Guglielmo Di Molfetta, Wagner S. Brum, Ilaria Pola, Kübra Tan, Andrea L. Benedet, Mathias Sauer, Laia Montoliu-Gaya, Shorena Janelidze, Niklas Mattsson-Carlgren, Nesrine Rahmouni, Tevy Chan, Marisa N. Denkinger, Petroula Proitsi, Henrik Zetterberg, Oskar Hansson, Pedro Rosa-Neto, Nicholas J. Ashton","doi":"10.1001/jamaneurol.2026.2650","DOIUrl":"https://doi.org/10.1001/jamaneurol.2026.2650","url":null,"abstract":"Importance Phosphorylated tau-217 (p-tau217) is now an established plasma biomarker for assessing amyloid-β pathology in individuals at risk of Alzheimer disease. However, its performance in identifying advanced neocortical neurofibrillary tangle burden remains suboptimal. Precise assessment of tau pathology is increasingly critical for the rational implementation of anti-amyloid therapies and developing anti-tau interventions. Improved biofluid biomarker–based tau staging could enhance patient stratification and optimize participant selection for clinical care and therapeutic trials. Objective To develop and validate a multiprotein plasma panel to improve identification of neocortical tau pathology beyond p-tau217 alone. Design, Setting, and Participants This multicenter cohort study included 2 independent observational cohorts, Swedish BioFINDER study and Translational Biomarkers in Aging and Dementia (TRIAD). Cross-sectional clinical data and blood samples were collected between 2017 and 2024. Participants included 560 individuals spanning the clinical spectrum from cognitively unimpaired to dementia. These data were analyzed from January 2025 to May 2026. Exposures Plasma concentrations of 125 proteins measured using Nucleic Linked Immuno-Sandwich Assay central nervous system panel. Main Outcome and Measure Advanced tau pathology defined as tau positron emission tomography (PET) uptake within Braak stage V and VI regions. Predictive performance of biomarker models was evaluated using area under the receiver operating characteristic curve (AUC). Results The study included 560 amyloid-positive participants (BioFINDER: n = 431; mean [SD] age, 73.6 [7.0] years; 212 female [49.2%] and 219 male [51.8%]; TRIAD: n = 129; mean [SD] age, 70.4 [8.3] years; 76 female [58.9%] and 53 male [41.1%]). Using multivariable logistic regression approaches, a 7-protein panel was found in BioFINDER to identify tau PET uptake within Braak stage V and VI regions. When compared with p-tau217 (AUC, 0.86-0.88; 95% CI, 0.82-0.94), this multiprotein panel was associated with improved identification in both discovery and validation cohorts (AUC, 0.92-0.94; 95% CI, 0.89-0.98; DeLong <jats:italic toggle=\"yes\">P</jats:italic> &amp;amp;lt; .001). This reduced the proportion of individuals classified within the intermediate-risk range (between paired sensitivity and specificity thresholds) in the validation cohort by 14.7% to 21.0%. Conclusions and Relevance This multicohort study demonstrated how including additional plasma proteins significantly enhanced the performance of p-tau217 in predicting advanced tau pathology among amyloid-positive individuals. This suggests a multiprotein approach may offer a viable and scalable alternative to tau PET staging in clinical or research settings.","PeriodicalId":14677,"journal":{"name":"JAMA neurology","volume":"56 1","pages":""},"PeriodicalIF":29.0,"publicationDate":"2026-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148698841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global and Partial Cataplexy, Geste Antagoniste, and Startle Response in Narcolepsy Type 1.","authors":"Roberta Di Giacomo, Lorella Pesce, Giuseppe Didato","doi":"10.1001/jamaneurol.2026.2543","DOIUrl":"https://doi.org/10.1001/jamaneurol.2026.2543","url":null,"abstract":"","PeriodicalId":14677,"journal":{"name":"JAMA neurology","volume":" ","pages":""},"PeriodicalIF":23.6,"publicationDate":"2026-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148663796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}